ERGOMED is a global specialist service provider for the pharmaceutical and biotechnology industries, established in 1997. The company supports drug development by offering comprehensive clinical research and pharmacovigilance services across all phases of clinical trials, from early development to post-marketing surveillance. With a presence in over 100 countries, ERGOMED effectively manages complex clinical development challenges for more than 300 clients, including major pharmaceutical companies and smaller drug developers.

The company provides full-service clinical trial management, including trial design, patient recruitment, site management, and regulatory affairs, with a particular focus on oncology and rare disease trials. ERGOMED also offers end-to-end drug safety services under the PrimeVigilance brand, covering the entire drug lifecycle. Additionally, through ADAMAS Consulting, it ensures regulatory compliance with GxP audits. ERGOMED's expertise in oncology is highlighted by its extensive portfolio of over 450 oncology studies, addressing various cancer types.